Ce Wang

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

J. Langston, K. Bromberg, M. Michaelides, 2017, ACS medicinal chemistry letters.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Chunaram Choudhary, Saul H. Rosenberg, Ronen Marmorstein, 2017, Nature.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Mikkel A. Algire, L. Lam, Chaohong Sun, 2017, Nature.